SINGAPORE · MEDICAL DEVICES

Singapore COVID-19 IVDs Move to Class C: Submitting After the IVD Cluster

From 2 June 2026, Singapore’s HSA reclassified COVID-19 in vitro diagnostic medical devices from Class D to Class C. On the same date, the “IVD Cluster” grouping in GN-12-1 ceased to apply. The first change alters the risk class of COVID-19 IVDs; the second changes the basis on which some IVDs can be combined in one application. The two need to be handled separately. (Sources: HSA industry briefing, 20 May 2026, pp. 17 and 21; HSA IVD Cluster page)

For manufacturers of COVID-19, influenza and RSV combination tests, the practical task is to re-check every configuration they intend to sell. Adding or dropping analytes, changing the intended use, or turning a professional-use version into a self-test can all affect the dossier and the application plan. Simply changing “Class D” to “Class C” on the application form does not complete that assessment.

What does each change affect?

ChangeDirect effectMisreading to avoid
COVID-19 IVDs from D to CCOVID-19 IVDs are regulated as Class C, aligned with other Class C IVDs.Down-classification does not remove the need for registration or performance evidence, nor does it automatically open an expedited route.
IVD Cluster withdrawnNew applications must use a grouping basis still available in GN-12-1 R3 or GN-12-2.Not all IVD groupings have gone, and it does not mean every catalogue number needs its own application.
Both on the same dateProduct classification and application grouping must be checked separately.Being “respiratory tests” is not enough to show that all configurations can be combined.

HSA’s briefing describes the IVD Cluster as a transitional “catch-all” grouping for Class A and Class B IVDs that eased mass registration when device controls were introduced; it also notes that Class A IVDs no longer require product registration. The withdrawal therefore does not mean that Class D COVID-19 products, or all respiratory combination tests, could previously use this grouping. (Source: HSA industry briefing, pp. 19–20)

HSA has said that specific grouping criteria such as IHC and FISH will be retained and expanded in GN-12-2. (Source: HSA industry briefing, p. 21) HSA’s current grouping page still lists Family, System, IVD Test Kit, Group and Single, plus specific groupings for IHC, FISH and IVD analysers, among others. (Source: HSA grouping page)

How should a combination test be classified?

First fix the intended purpose, target users, specimen types, analytes and how results are used. The COVID-19 analyte follows HSA’s June 2026 change; the other analytes in the same product still need to be checked one by one against the GN-14 IVD classification rules. GN-14 R3 states that a product with more than one intended purpose is classified in the higher class, and where several rules apply the highest risk class is assigned. Keep the reasoning in writing. (Source: GN-14 R3, pp. 10–11)

So for a multiplex panel that includes COVID-19, Class C is the starting point for the COVID-19 analyte, but the final class depends on the claims of the product as a whole. A configuration with a different clinical use, or one caught by a higher-risk rule, needs its own analysis. The class of an approved COVID-19 single test cannot simply be carried over to every new combination. Note that GN-14 R3 was published in 2023 and does not mention COVID-19; the reclassification rests on the change HSA announced in 2026.

Professional-use, self-testing and near-patient versions should also be listed separately. Under GN-14 Rule 4, IVDs for self-testing or near-patient testing are in principle Class C (some whose result is preliminary and requires follow-up with a laboratory test can be Class B); near-patient testing means testing performed outside a laboratory by a healthcare professional. (Source: GN-14 R3, pp. 6 and 15) Versions may share the same technology yet serve different operators and settings. For a self-test in particular, sampling, operation, interpretation of results and follow-up action need to be clear, and the user evidence must match the version to be sold.

With the Cluster gone, how do you choose a grouping?

Start with how the product is actually built and sold, then check it against the GN-12-1 R3 grouping criteria. The three most relevant to respiratory combination tests are summarised below:

GroupingMain criteria in GN-12-1 R3What to check for combination tests
Family (pp. 10–11)Same product owner, same risk class, common intended purpose, common design and manufacturing process, with variations within the permissible variants; the list of permissible variants is closed.Whether differences between 3-, 5- and 7-plex panels are permissible variants; a shared housing, brand or production line is not enough on its own.
IVD Test Kit (pp. 22–24)Reagents or articles from the same product owner, used in combination to complete a specific intended purpose; sold under a single kit name, or the labelling/IFU states each component is for use with the kit; compatible when used as a kit. Instruments such as analysers are not included.Labelling statements and compatibility for each component; components from another product owner need the additional information required.
System (pp. 18–20)Devices and/or accessories from the same product owner, used in combination for a common intended purpose, compatible when used as a system, with a single system name or labelling showing they are used together.Whether an instrument-plus-reagent offering forms a System; HSA’s specific IVD analysers grouping may also be relevant.

(Source: GN-12-1 R3, effective 2 June 2026)

For example, a manufacturer planning 3-plex, 5-plex and 7-plex tests should first tabulate each panel’s intended use, analytes, strip layout, reaction chemistry and user version. Once the common and differing elements are clear, choose the grouping basis. Different product claims should not be written up as one intended use just to reduce the number of applications.

Also distinguish the number of applications from the number of SMDR entries after approval. GN-12-1 R3 makes clear that grouping is for submission purposes only, and that the SMDR listing on approval may differ from the submitted grouping; for example, products with different proprietary or brand names are listed separately. Several SMDR entries appearing at the same time therefore neither prove nor rule out a combined application. (Source: GN-12-1 R3, p. 8)

Start with a configuration and evidence matrix

The approach below is MediPass’s suggested way for manufacturers and their Singapore registrant to agree the submission scope; it is not an HSA form. Each row represents a real configuration to be sold, so that the model list, IFUs, overseas approvals and performance reports all describe the same scope.

ItemDifferences to stateRecord to produce
Product and usersAnalyte panel, professional/self-test, specimen and clinical use.Configuration list with the classification reasoning for each.
Grouping basisShared design and manufacturing process; whether differences are permissible variants.Candidate grouping with supporting reasons; configurations it cannot cover listed separately.
Reference approvalsWhether approved models, analytes and labelled use match the Singapore version.Model-by-model approval scope comparison.
Performance and labellingWhich IFUs and configurations each analyte’s and panel’s evidence supports.Evidence index, version log and gap list.

Which Class C evaluation route?

Decide the route once configurations and grouping are settled. Class C does not automatically mean Expedited Class C Registration (ECR). HSA lists the following Class C routes and conditions:

RouteConditions stated by HSA
FullNo prior approval by any of HSA’s overseas reference regulatory agencies.
AbridgedApproval from at least one reference agency.
ECR-1Approval from at least one reference agency; marketed for at least three years in that agency’s jurisdiction; no safety issues globally in the last three years (no reported deaths or serious deterioration in health, and no open field safety corrective actions at submission); no prior rejection or withdrawal by HSA or any reference agency.
ECR-2Currently approved by at least two reference agencies; no prior rejection or withdrawal by HSA or any reference agency. EU or TGA approvals count as independent reference approvals only if the agency itself reviewed and approved the device, not if it was registered under a Mutual Recognition Agreement (MRA).

For Abridged and ECR, the reference approvals must be for the same labelled use as the device intended for Singapore. An overseas approval for a professional-use version therefore cannot serve as the reference approval for a self-test, and a product without a suitable reference approval cannot move to a shorter route merely because it has been down-classified. (Sources: HSA registration overview; HSA Class C expedited route page)

Define evidence gaps panel by panel: which analytes, specimen types and users does a given clinical report cover? Has a newly added test line been validated? Where several configurations share evidence, record the technical rationale for sharing and what cannot be extrapolated. With an evidence index per configuration, the manufacturer and registrant can discuss specific gaps and the order in which to close them. For the overall process, see our Singapore medical device registration and IVD registration pages.

What about registered products and pending applications?

Start by recording existing registration or application numbers, approved class, models and labelling versions. The HSA public materials we reviewed (the industry briefing, the IVD Cluster and grouping pages, and GN-12-1 R3) do not set out transitional arrangements for registered or pending products. Where grouping, fees or class in a pending application may be affected, we suggest the registrant confirm the handling with HSA, quoting the specific application numbers and configuration differences, before updating the system records.

Check UDI and labelling separately as well. A change in risk class may affect which UDI arrangements apply, but it should not be assumed that nothing needs to be done. We suggest keeping UDI status, packaging versions and planned import batches in the project matrix, and having the registrant confirm the requirements for the new class against HSA’s current rules.

Frequently asked questions

After the change, are all respiratory combination tests Class C?
Assess against the full intended use and every applicable rule. The COVID-19 change does not replace the analysis of other analytes, users and clinical situations; where several rules apply, the highest class applies. The final class follows once the product scope is fixed.

If several products are all for “respiratory infection”, can they go in one application?
That description is too broad. Compare analytes, specific intended use, design, manufacturing process and permissible variants, and show which valid grouping criteria are met. Sharing a disease area or brand is not enough.

The professional-use version has an overseas approval. Can the self-test use Abridged or ECR?
HSA requires reference approvals for the same labelled use as the Singapore version. An approval for the professional-use version does not support the self-test; the self-test needs its own suitable reference approval, otherwise it should be prepared for the Full route.

Does Class C mean less performance data?
The evidence must support the actual claims of the product to be sold and meet the chosen evaluation route. The reclassification is no reason to drop evidence needed for added analytes or self-test use, and an existing single-test report does not automatically cover every combination.

Official references

  1. HSA, Medical Devices Industry Briefing: Regulatory Updates, p. 17: COVID-19 IVDs reclassified from Class D to Class C; pp. 19–21: IVD Cluster withdrawal, 20 May 2026, file.go.gov.sg (PDF)
  2. HSA, Grouping medical devices as an IVD Cluster (withdrawal notice), page updated 28 May 2026, hsa.gov.sg
  3. HSA, GN-12-1 R3 Guidance on Grouping of Medical Devices for Product Registration (general grouping criteria), p. 8: SMDR listing; pp. 10–11: Family; pp. 18–20: System; pp. 22–24: IVD Test Kit, effective 2 June 2026, file.go.gov.sg (PDF)
  4. HSA, Grouping of medical devices (current list of groupings), page updated 5 October 2026, hsa.gov.sg
  5. HSA, GN-14 R3 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices, p. 6: near-patient testing definition; pp. 10–11: multiple purposes/rules, higher class applies; p. 15: Rule 4, effective 24 July 2023, hsa.gov.sg (PDF)
  6. HSA, Overview of medical device registration (evaluation routes), page updated 13 March 2026, hsa.gov.sg
  7. HSA, Register Class C medical device via expedited route (ECR-1/ECR-2 criteria), page updated 13 March 2026, hsa.gov.sg

Prepared from official sources verifiable as of 7 October 2026. It distinguishes changes HSA has published from project suggestions for manufacturers; registered or pending products should be confirmed with HSA according to their registration status.

Leave a Comment

Your email address will not be published. Required fields are marked *

Chat on WhatsAppWhatsApp 咨询